Send us Feedback

Abraxis BioScience (ABII)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ABII » Topics » 15. Segment Information

This excerpt taken from the ABII 10-K filed Mar 12, 2010.

17. Segment Information

We operate in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

This excerpt taken from the ABII 10-K filed Mar 6, 2009.

14. Segment Information

We operate in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

 

89

Table of Contents
This excerpt taken from the ABII 10-Q filed May 15, 2008.

(8) Segment Information

We operate in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

These excerpts taken from the ABII 10-K filed Mar 31, 2008.

13. Segment Information

We operate in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

13. Segment Information

SIZE="2">We operate in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

SIZE="2">14. Subsequent Events

We have signed agreements to acquire 100% of the equity of certain biotechnology and specialty
pharmaceutical companies for an initial up-front payment at closing of $15.0 million plus additional payments upon achievement of certain milestones.

SIZE="2">15. Unaudited Quarterly Financial Data

Selected quarterly data for years end December 31, 2007 and 2006 was as
follows:

 



























































































































































































































































   Year Ended December 31, 2007 
  First  Second  Third  Fourth 
   (in thousands, except per share data) 

Net revenue

  $71,893  $83,217  $87,791  $90,785 

Gross profit

  $64,234  $76,318  $76,173  $82,511 

Net loss

  $(5,671) $(13,971) $(16,772) $(5,190)

Loss per common share(1):

     

Basic and diluted

  $(0.14) $(0.35) $(0.42) $(0.13)
   Year Ended December 31, 2006 
  First  Second  Third  Fourth 
   (in thousands, except per share data) 

Net revenue

  $31,056  $40,484  $53,376  $57,371 

Gross profit

  $25,935  $34,405  $47,591  $53,173 

Net loss

  $(18,629) $(90,061) $(10,900) $(4,961)

Loss per common share(1):

     

Basic and diluted

  $(0.47) $(2.25) $(0.27) $(0.12)

 





(1)As of the completion of the separation, on November 13, 2007, we had 40.0 million common shares outstanding. The same number of shares is being used for both diluted
earnings per share and basic earnings per share for all periods prior to the separation date.

 


92






Table of Contents


This excerpt taken from the ABII 8-K filed Nov 8, 2007.

15. Segment Information

New Abraxis operates in one business segment. Therefore, the results of operations are reported on a combined basis for purpose of segment reporting.

EXCERPTS ON THIS PAGE:

10-K
Mar 12, 2010
10-K
Mar 6, 2009
10-Q
May 15, 2008
10-K (2 sections)
Mar 31, 2008
8-K
Nov 8, 2007

RELATED TOPICS for ABII:

"15. Segment Information" elsewhere:

Genzyme (GENZ)
Adherex Technologies (ADH)
Celldex Therapeutics, Inc. (AVAN)
Avalon Pharmaceuticals (AVRX)
BioSphere Medical (BSMD)
CollaGenex Pharmaceuticals (CGPI)
Chemgenex Pharmaceuticals (CXSP)
Eclipsys (ECLP)
Eurand N.V. (EURX)
Fibrocell Science, Inc. (ILE)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki